MNMD - MindMed Inc.

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Twiggs462, Apr 24, 2021.

  1. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
    Analysts - Psychedelics Industry Potential $400 Billion Annual Revenue

    Looking at the H.C. Wainwright's analysis / industry update.

    Mind Medicine; MNMD; Buy; $5 price target (lowered from $10 /share). MindMed ended 2Q22 with cash and investments of $98M, which is expected to be sufficient to meet its operating requirements beyond key development milestones into 2024 according to the latest 10-Q filing. On August 11, MindMed announced progress on MM-120, a proprietary and pharmaceutically optimized form of lysergic acid diethylamide (LSD), which advanced to Phase 2b in generalized anxiety disorder (GAD) though also announced a pause to clinical development of zolunicant, a non-psychedelic form of ibogaine, which we had believed to be among the most valuable programs in the mental healthcare space primarily as it had potential to address the out of control opioid epidemic in America. However, on the 2Q22 earnings call, management noted that additional preclinical work would be needed to advance zolunicant in opioid use disorder (OUD); MindMed is to seek nondilutive sources of capital and/or a collaboration prior to advancing the program; as such, we have, for now, removed the program from our estimates. On the positive side, the Phase 2b dose-optimization trial evaluating MM-120 (Project Lucy) is expected to dose the first patient in 3Q22 with top-line data expected in late 2023. As such, in our August 16 update, issued today, we reduced our price target to $10 from $5 to reflect the removal of zolunicant from our estimates Separately, we note that Investigational New Drug (IND)-enabling studies evaluating MM-402, an R-enantiomer of MDMA, are ongoing, with a Phase 1 clinical trial expected to initiate in 2023; MM-402 is expected to be evaluated as a potential treatment for the core symptoms of autism spectrum disorder (ASD). For additional details on the strategic update, refer to our August 16 update entitled, Potential Blockbuster LSD Program Progressing; 18-MC Addiction Program to Be Partnered; Lowering Price Target to $5 . For additional details on LSD in anxiety, refer to our May 11 update entitled Positive Phase 2 Top-Line Results for LSD in Anxiety Provides Positive Read Through to MM-120; Reiterate Buy , and to our August 5, 2021, initiation of coverage report entitled Building the Mental Healthcare Treatment Paradigm of the Future; Initiating With a Buy and $10 Price Target .

    https://hcwco.bluematrix.com/sellsi...c71b9470-8122-49bc-a2ee-c43b0e9c7445&mime=pdf
     
    Rayak likes this.
  2. Rayak

    Rayak Member

    Joined:
    Jul 30, 2022
    Messages:
    65
    Likes Received:
    40
    I just bought 100 shares of MNMD. With some analysts predicting price targets in the $5 to $10/share range, I figured, 'why not?'
     
  3. Andrew Peter O'Donovan

    Joined:
    Jun 8, 2020
    Messages:
    25
    Likes Received:
    14
    Up 50% for the day..
     
    Rayak likes this.
  4. Rayak

    Rayak Member

    Joined:
    Jul 30, 2022
    Messages:
    65
    Likes Received:
    40
    What's amazing is that if the data my brokerage is supplying is correct, todays MNMD volume accounts for over 30% of the total outstanding shares!?! That's a lot of profit taking.
     
  5. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
    Volume was unreal today.
     
  6. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
  7. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
  8. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
    MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

    https://www.prnewswire.com/news-rel...n-generalized-anxiety-disorder-301612131.html

    NEWS PROVIDED BY
    Mind Medicine (MindMed) Inc.
    Aug 25, 2022, 07:30 ET

    NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD).

    "The initiation of our Phase 2b clinical trial, the largest well-controlled clinical trial of LSD ever conducted, represents a major milestone for MindMed and for the many patients suffering from GAD," said Robert Barrow, Chief Executive Officer and Director of MindMed. "This exciting next step in the advancement of LSD builds on the positive topline data presented by our partners at University Hospital Basel in May 2022, which demonstrated the rapid, durable, and statistically significant effects of LSD and its potential to safely mitigate symptoms of anxiety and depression. The results of our Phase 2b trial will guide the dose selection and development strategy for our pivotal Phase 3 clinical trials, as we continue our efforts to bring a new potential treatment to the millions of people living with GAD."

    The Phase 2b trial in patients diagnosed with GAD is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study. The trial plans to enroll 200 participants who will receive a single administration of up to 200 µg of MM-120 or placebo. The primary objective is to determine the reduction in anxiety symptoms 4 weeks after a single administration of MM-120, compared across the five treatment arms. Key secondary objectives, measured up to 12 weeks after the single administration, include assessments of safety and tolerability as well as quality of life. More information about the trial is available on our website (mindmed.co) or on clinicaltrials.gov (identifier NCT05407064).
    About Generalized Anxiety Disorder (GAD)

    GAD is a chronic, often debilitating mental health disorder that affects approximately 6% of U.S. adults in their lifetimes. Symptoms of GAD include excessive anxiety and worry that persists for over six months, which can lead to significant impairments in social, occupational and other functioning, according to the National Institute of Mental Health (NIMH). While there is substantial diagnostic overlap between GAD, Major Depressive Disorder (MDD) and other major mental health disorders, there has been very little innovation focused on the treatment of GAD in the past several decades.

    About MindMed

    MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
    MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
     
  9. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
  10. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
  11. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
    ARK on investing investing in this space:

     
  12. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
  13. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
    Big things coming concerning stolen IP - going to get interesting here.
     
  14. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
  15. Rayak

    Rayak Member

    Joined:
    Jul 30, 2022
    Messages:
    65
    Likes Received:
    40
    Twiggs462 likes this.
  16. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
    I think we will see that... the recent price action is fear. This company is going to go crazy in due time.
     
  17. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
    Friederike Holze on LSD and anxiety

     
  18. Rayak

    Rayak Member

    Joined:
    Jul 30, 2022
    Messages:
    65
    Likes Received:
    40
    I would probably agree - IF - and that looks like a fairly questionable IF now - this Hurst scammer hasn't poisoned the water.

    Psychedelic therapeutics have a pretty substantial PR burden to begin with. I hope this fraudster hasn't created a situation where the company won't ever be taken seriously.
     
  19. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4
  20. Twiggs462

    Twiggs462 Member

    Joined:
    Dec 6, 2020
    Messages:
    101
    Likes Received:
    4

Share This Page